Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person14
Momentum Transport Planning Limited
Company · 08234059
Experian Limited
Company · 00653331
PLAYSCAN LIMITED
Company · 01966393
Learning Pool Limited
Company · NI060102
Placecube Limited
Company · 09914106
EXCOOL LIMITED
Company · 07153492
GB WELLNESS EXPERT LIMITED
Company · 12658230
E.I.R.P Limited
Company · 02904597
Plane Perspective Limited
Company · 08355175
Haskoning UK Limited
Company · 01336844
Exotopic Limited
Company · 09238982
Pluxee UK Limited
Company · 02680629
Access UK Limited
Company · 02343760
Pennington Choices Limited
Company · 03945920
Primary record16
AST SpaceMobile, Inc. filed 8-K
Item 7.01. Regulation FD Disclosure. On November 6, 2026, AST SpaceMobile, Inc. (the “Company”) issued a press release regarding its plan to build its own 20-ton rocket to deploy BlueBird satellites in low-Earth orbit us
TuHURA Biosciences, Inc./NV filed 8-K
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered in
Driven Brands Holdings Inc. filed NT 10-Q
Item 4.02 on November 3, 2026 (the “Restatement”). The errors described above were identified after the filing of the 2025 Form 10-K, principally while preparing the fiscal year 2025 financial statements of certain of it
CURIS INC filed 8-K
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 2, 2026, Curis, Inc. (the “Company”) received a letter (the “Delist Determination Letter”) from
Acrivon Therapeutics, Inc. filed 8-K
Item 8.01 Other Events. On November 6, 2026, Acrivon Therapeutics, Inc., a Delaware corporation (the “ Company ”), announced that it has entered into an asset purchase agreement (the “ Purchase Agreement ”) with Aqilion
Crown PropTech Acquisitions filed 8-K
Item 8.01 Other Events. On November 5, 2026, Mkango announced that, on November 4, 2026, the U.S. Securities and Exchange Commission (the “ SEC ”) declared effective the registration statement on Form F-4 (File No. 333-2
TKO Group Holdings, Inc. filed 8-K
Item 8.01 Other Events. On November 5, 2026, TKO Group Holdings, Inc. (the “Company” or “TKO”) announced the commencement of an offering (the “Offering”) of $1.0 billion in aggregate principal amount of Senior Secured No
Profusa, Inc. filed 8-K
Item 1.01. Entry into a Material Definitive Agreement. The information set forth under Item 2.03 below is hereby incorporated herein by reference. Item 2.03. Creation of a Direct Financial Obligation or an Obligation und
First Breach, Inc. filed 8-K
Item 7.01. Regulation FD Disclosure. On November 3, 2026, First Breach Inc. (the “Company”) issued a press release announcing certain supply agreements and equipment additions in support of the Company’s ammunition produ
Strive, Inc. filed 8-K
Item 2.02. Results of Operations and Financial Condition. On November 6, 2026, Strive, Inc. (the “Company” or "Strive") issued a press release announcing the Company’s financial results for the quarter ended September 30
MOLINA HEALTHCARE, INC. filed 8-K
Item 7.01. Regulation FD Disclosure. 2026 Outlook Affirmation Members of the senior management team of Molina Healthcare, Inc. (“Molina” or the “Company”) will be participating in UBS’s Global Healthcare Conference on Mo
TEG OVERSEAS, INC. filed 8-K
Item 7.01. Regulation FD Disclosure. On November 3, 2026, TEG SPV LLC, a limited liability company organized under the laws of the Republic of Uzbekistan (“TEG SPV”) and a substantially wholly-owned subsidiary of TEG Ove
Pono Capital Four, Inc. filed 8-K
Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, on August 5, 2026, Pono Capital Four, Inc. (“Pono” or “Parent”), a Cayman Islands exempted company (which shall de-register from the Registe
INTRUSION INC filed 8-K
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 4, 2026, Intrusion Inc. (the “Company”) received formal written notification from the Listing Qua
Karyopharm Therapeutics Inc. filed 8-K
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on November 2, 2026, Karyopharm Therapeutics Inc. (the “Company”) and its subsidiar
Enova International, Inc. filed 8-K
Item 8.01 Other Events. 2031 Notes Pricing On November 5, 2026, Enova International, Inc. (the “Company”) priced its previously announced private offering of $600 million aggregate principal amount of senior notes due 20